Fortis Technologies has produced a new application note showing the successful analysis of Tamiflu (Oseltamivir) on its silica based Fortis C18 column.
The official method approved by the Centre for Disease Control and Prevention (CDC) shows that the best option for the analysis of Oseltamivir is by the use of high pH mobile phase to neutralise the analyte.
A Fortis C18 column is used in this application due to its ability to work with high pH mobile phase systems.
Based upon a silica particle template the bonding process of Fortis C18 allows the full use of the pH range from 1-12 without the need for a hybrid technology.
By being able to operate on a silica particle means no loss of efficiency, loadability or speed of equilibration is seen.
Scalability and ease of method transfer from UHPLC through to Preparative chromatography is maintained in the simplest of fashion.
To download the full report, please click on the link above.
